(Photo Courtesy: www.aerodna.com)
India remains an important growth market for Bactiguard.
The cooperation with Cadila Pharmaceuticals, which was initiated in 2012 has, however, not provided the regulatory and market related benefits expected at the time, said the company's press statement.
Therefore, Bactiguard is evaluating an alternative sales strategy, which paves the way for market launch and initiation of sales in 2015, as planned.
Preparations for the launch and clinical studies are well under way.
As a result of the above changes in strategy, Bactiguard has decided to make reservations in the interim results for the first quarter of 2015 for doubtful receivables, with a negative effect on results of approximately Million Swedish Kroner (MSEK) 24.